---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000031"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:48:59.390078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics grants 177,000 RSUs to CEO and 20,000 RSUs to SVP in annual equity awards

## Summary
- CEO René Russo granted 177,000 restricted stock units effective Jan 1, 2024.
- SVP Kevin Brennan granted 20,000 restricted stock units effective same date.
- RSUs vest in four equal annual installments beginning Jan 1, 2025, subject to continued service.
- Awards granted under 2021 Stock Incentive Plan; form agreement filed as Exhibit 10.1.

## SEC filing metadata
- accession: 0001558370-24-000031
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/0001558370-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/xlo-20240101x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000031
- JSON: https://secwatch.observer/filing/0001558370-24-000031.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.